Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
StockStory.org on MSN
Why are Novavax (NVAX) shares soaring today
What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the ...
Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...
Pharmaceutical Technology on MSN
Pfizer and Novavax ink $530m vaccine delivery licensing deal
Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.
At the 44th Annual J.P. Morgan Healthcare Conference on 14 January 2026, Novavax outlined a new partner-led business model, ...
Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results